A practical reference on ghrelin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-14 and is reviewed periodically as new material appears.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
Multiple testing was done to be able to narrow down whether his form of Syncope is caused by mental factors or cardiac abnormalities, the results are still pending. Dr. Lisa Sanders took Matt’s story to the column and awaited for responses from the audience with ideas. Out of the hundreds of responses, only two were the most cohesive towards Matt’s symptoms. The first possibility was Vasovagal Syncope, where the nervous system will send an incorrect message too slow down the heart and can cause it to stop, the tilt table test performed on Matt could provide a definitive answer to this theory. The second possibility is Temporal lobe epilepsy which is a kind of seizure that is correlated to a sense of “strange” thoughts, feelings, or sense of Deja Vu. Matt was subjected to an EEG which did not show any preliminary seizure disorders, however the specialist who reviewed his results noted that the EEG might not express any deep temporal lobe seizures. The tilt table test performed on Matt came back negative for Vasovagal Syncope, however Matt was fitted with a heart tracker to be able to detect any abnormal signals within the heart during an episode. Matt finally had an episode with his heart loop tracker, the tracker was able to detect a 6 second heart stop during his episode. On the same day Matt had this episode he had another one once his stress level started to rise, this was the first time in the entire duration of his illness that he's had two episodes in one day. Dr.
The Treaty established that the new state would be a constitutional monarchy, with the Governor-General of the Irish Free State as the representative of the Crown. The Constitution of the Irish Free State made more detailed provision for the state's system of government, with a three-tier parliament, called the Oireachtas, made up of the king and two houses, Dáil Éireann and Seanad Éireann (the Irish Senate). Executive authority was vested in the king, with the Governor-General as his representative. He appointed a cabinet called the Executive Council to "aid and advise" him. The Executive Council was presided over by a prime minister called the President of the Executive Council. In practice, most of the real power was exercised by the Executive Council, as the Governor-General was almost always bound to act on the advice of the Executive Council.
T1-mapping (notably used in cardiac magnetic resonance imaging) T2-mapping Quantitative susceptibility mapping (QSM) Quantitative fluid flow MRI (i.e. some cerebrospinal fluid flow MRI) Magnetic resonance elastography (MRE) Magnetic resonance fingerprinting (MRF) Quantitative MRI aims to increase the reproducibility of MR images and interpretations, but has historically require longer scan times. Quantitative MRI (or qMRI) sometimes more specifically refers to multi-parametric quantitative MRI, the mapping of multiple tissue relaxometry parameters in a single imaging session. Efforts to make multi-parametric quantitative MRI faster have produced sequences which map multiple parameters simultaneously, either by building separate encoding methods for each parameter into the sequence, or by fitting MR signal evolution to a multi-parameter model.
=== Diet === People who follow the prescribed dietary treatment from birth may (but not always) have no symptoms. Their PKU would be detectable only by a blood test. People must adhere to a diet low in Phe for optimal brain development. Since Phe is necessary to synthesize most proteins, it is required for appropriate growth, but levels must be strictly controlled.
In a positive review in The New York Times, Jennifer Senior wrote that Vance's confrontation of a social taboo was admirable, regardless of whether the reader agreed with his conclusions. She described the book as "a compassionate, discerning sociological analysis of the white underclass that has helped drive the politics of rebellion, particularly the ascent of Donald J. Trump." Senior wrote that Vance's subject is despair, and his argument was more generous in that it blames fatalism and learned helplessness rather than indolence. A 2017 Brookings Institution report noted that "J. D. Vance's Hillbilly Elegy became a national bestseller for its raw, emotional portrait of growing up in and eventually out of a poor rural community riddled by drug addiction and instability." Vance's account anecdotally confirmed the report's conclusion that family stability is essential to upward mobility. In an interview with Süddeutsche Zeitung in July 2023, German chancellor Olaf Scholz called the book "a very touching personal story of how a young man with poor starting conditions makes his way." Scholz said the book had moved him to tears, but that he found the positions Vance later took to be "tragic." The book was positively received by conservatives such as National Review columnist Mona Charen and National Review editor and Slate columnist Reihan Salam. American Conservative contributor and blogger Rod Dreher expressed admiration for Hillbilly Elegy, saying that Vance "draws conclusions... that may be hard for some people to take. Vance has earned the right to make those judgments.
Sources: en.wikipedia.org
Patient may feel itchy or having hives but the symptoms are usually mild and can be controlled by stopping the transfusion and giving antihistamines. Anaphylactic reactions are rare life-threatening allergic conditions caused by IgA anti-plasma protein antibodies. For patients who have selective immunoglobulin A deficiency, the reaction is presumed to be caused by IgA antibodies in the donor's plasma. The patient may present with symptoms of fever, wheezing, coughing, shortness of breath, and circulatory shock. Urgent treatment with epinephrine is needed. Post-transfusion purpura is an extremely rare complication that occurs after blood product transfusion and is associated with the presence of antibodies in the patient's blood directed against both the donor's and recipient's platelets HPA (human platelet antigen). Recipients who lack this protein develop sensitization to this protein from prior transfusions or previous pregnancies, can develop thrombocytopenia, bleeding into the skin, and can display purplish discolouration of skin which is known as purpura. Intravenous immunoglobulin (IVIG) is treatment of choice. Transfusion-related acute lung injury (TRALI) is a syndrome that is similar to acute respiratory distress syndrome (ARDS), which develops during or within 6 hours of transfusion of a plasma-containing blood product. Fever, hypotension, shortness of breath, and tachycardia often occurs in this type of reaction.
=== Long-chain hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency === Long-chain hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency is a mitochondrial effect of impaired enzyme function. LCHAD performs the dehydrogenation of hydroxyacyl-CoA derivatives, facilitating the removal of hydrogen and the formation of a keto group. This reaction is essential for the subsequent steps in beta oxidation that lead to the production of acetyl-CoA, NADH, and FADH2, which are important for generating ATP, the energy currency of the cell. Long-chain hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency is a condition that affects mitochondrial function due to enzyme impairments. LCHAD deficiency is specifically caused by a shortfall in the enzyme long-chain 3-hydroxyacyl-CoA dehydrogenase. This leads to the body's inability to transform specific fats into energy, especially during fasting periods. Symptoms
=== Judicial === The Rhodesian High Court's nine Appellate and General Division judges initially neither rejected UDI nor openly supported it. The Chief Justice Sir Hugh Beadle, of the Appellate Division, announced simply that the judges would go on carrying out their duties "according to the law". This originally noncommittal stance evolved over time, largely pivoting around legal cases argued at the High Court in Salisbury between 1966 and 1968. The first of these, Madzimbamuto v. Lardner-Burke N. O. and Others, concerned Daniel Madzimbamuto, a black Rhodesian who was detained without trial by the Rhodesian government on 6 November 1965, the day after the declaration of a state of emergency and five days before UDI, on the grounds that he might pose a danger to the public. Desmond Lardner-Burke, the Rhodesian Minister of Justice and Law and Order, prolonged the state of emergency in February 1966, prompting Madzimbamuto's wife to appeal for his release, arguing that since the United Kingdom had declared UDI illegal and outlawed the Rhodesian government with the Southern Rhodesia Act 1965, the state of emergency (and, by extension, Madzimbamuto's imprisonment) had no legal basis. The General Division of the Rhodesian High Court ruled on 9 September 1966 that legal sovereignty lay with the British government, but that to "avoid chaos and a vacuum in the law" the Rhodesian government should be considered to be in control of law and order to the same extent as before UDI.
=== Pathways === Until recently, necrosis was thought to be an unregulated process. However, there are two broad pathways in which necrosis may occur in an organism. The first of these two pathways initially involves oncosis, where swelling of the cells occurs. Affected cells then proceed to blebbing, and this is followed by pyknosis, in which nuclear shrinkage transpires. In the final step of this pathway cell nuclei are dissolved into the cytoplasm, which is referred to as karyolysis. The second pathway is a secondary form of necrosis that is shown to occur after apoptosis and budding. In these cellular changes of necrosis, the nucleus breaks into fragments (known as karyorrhexis).
== History == Twinlab was founded by David and Jean Blechman in 1968 and run by them and their sons – Neil, Brian, Ross, Steve and Dean. Using experience gained from over 20 years as a pharmaceutical salesman, David Blechman named the company for his two sets of twins and started marketing a liquid protein supplement from their family garage. Sales of Twinlab's only product skyrocketed in the 1970s, in part from the success of a 1976 book entitled The Last Chance Diet — When Everything Else Has Failed: Dr. Linn's Protein-Sparing Fast Program. Dr. Robert Linn was a Pennsylvania osteopath, who had begun prescribing for his overweight patients a program of fasting and four- to six-ounce daily doses of liquid protein. His book sold extremely well, and Dr. Linn's diet became the latest weight-loss fad diet. This led to increased sales for Twinlab's liquid protein. As with many fad diets, the fasting/liquid protein craze came to a halt when in late 1976 and early 1977 there were reports of the deaths of 58 people who had followed Linn's diet. Following a U.S. Food and Drug Administration (FDA) investigation the associated coverage of the popular diet and its potential side effects by Newsweek, Parents' Magazine, and Science Digest, the liquid protein market bottomed out, and Twinlab's revenues declined sharply forcing the company to cut nearly all of its 150-person workforce. In the 1980s Twinlab branched out formulating new vitamin and nutritional supplements and purchased a publishing company called Advanced Research Press, Inc.
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.